CaliPharms EBIT

The latest EBIT for KGET is $-820K as of September 2014. That compares with $-110K in the prior-year period — down 662.4% year over year. That is below the Industrials sector average of $41B. Investors often review this figure alongside CaliPharms's historical trend and sector peers before judging valuation or financial health.

Over the past year, KGET's EBIT moved from $-110K to $-820K — a 662.4% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in CaliPharms's operating scale or balance-sheet position.

Against Industrials companies, KGET currently prints $-820K for EBIT, while the sector average sits near $41B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at CaliPharms's growth, margins, and balance sheet.

A EBIT figure of $-820K for KGET is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Industrials average is about $41B. Explore the charts below for those layers of context.

After noting KGET's EBIT ($-820K), review year-over-year change from $-110K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.